Nov. 5 at 11:39 PM
$INVA Some updates from the earnings report that I was not aware of.
In August 2025, a substantial portion of the Company’s 2025 convertible noteholders elected to convert an aggregate principal balance of
$192.5 million into 11.1 million shares of Innoviva common stock prior to maturity.
In August 2025, Innoviva invested
$15.0 million in a term loan to Armata Pharmaceuticals, which recently announced positive Phase 2 data in Staphylococcus aureus bacteremia.
In September 2025, Innoviva acquired a proprietary long-acting oral drug delivery platform and related assets from Lyndra Therapeutics, Inc. The transaction included an upfront payment of
$10.2 million, plus potential milestone and royalty payments.
In October 2025, Innoviva invested
$17.5 million in the Series B Preferred Stock of Beacon Biosignals, Inc., an AI-driven neurotechnology company developing treatments for neurological, psychiatric, and sleep disorders.
